EuroPCR 2022 | Changes in Cardiac Damage after Surgical Aortic Valve Replacement

This study presented at EuroPCR 2022 analyzed the PARTNER study pool and included 1974 patients with a complete echocardiogram.

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico  por cirugía

Surgical risk was 17.3% extreme/inoperable, 54.3% intermediate and 28.4% low.

60% received transcatheter aortic valve replacement (TAVR) and the rest surgical aortic valve replacement (SAVR). 

6.1% of patients were in stage 0 (no damage), 14.5% were in stage 1 (left ventricular damage), 51.4% in study 2 (mitral or left ventricular damage), 20.9% in stage 3 (pulmonary vascular or tricuspid damage) and 7.1% were in stage 4 (right ventricular damage).

Baseline damage was associated with mortality at 2 years with both strategies, as was the composite of death and rehospitalization for cardiac failure. This was maintained after adjusting for variables at one-year followup. 

Cardiac damage remained unchanged in 60% of patients and worsen in 25%. 

At 2 years, morality for stages 0, 1, 2 ,3 and 4 was 2.5%, 7.1%, 14.6%, 28,2% and 28.2% respectively; and for mortality and rehospitalization for cardiac failure, it was 4.1% (stage 0), 13.4% (stage 1), 22.9% (stage 2), 38.7% (stage 3) and 39% (stage 4).

Read also: Should Total Occlusion Influence on Revascularization Strategy?

Improved myocardial damage was associated with lower mortality and rehospitalization for cardiac failure, and worse myocardial damage increased these events. 

Independent predictors of stage worsening were hypertension (OR 1.73; 95% CI 1.01-2.96) and SAVR (OR 2.04; 95% CI 1.52-2.74).

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Source: TCTmd.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...